Response Genetics hopes to secure $1.9 million in a direct offering of shares. The Los Angeles molecular diagnostics company will use the money to expedite integration of the Tissue of Origin assay it acquired from Pathwork Diagnostics. The test has FDA clearance for identifying undifferentiated, poorly differentiated and metastatic cancers.
Calif. molecular Dx firm could bring in $1.9M from stock sale
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||